RecruitingPhase 2NCT07598383

A Multicenter, Randomized, Double-blind, Vehicle Controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of VC005 Gel in Adult Subjects With Mild to Moderate Atopic Dermatitis

Sponsor

Jiangsu vcare pharmaceutical technology co., LTD

Enrollment

120 participants

Start Date

Jun 1, 2026

Study Type

INTERVENTIONAL

Conditions

Atopic Dermatitis

Summary

This is a multicenter, randomized, double-blind, vehicle controlled phase II clinical study to evaluate the efficacy and safety of VC005 gel in adult subjects with mild to moderate atopic dermatitis

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called VC005 Placebo group and a drug called VC005 group for people with atopic dermatitis. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGVC005 group

VC005 group with Local topical application

DRUGVC005 Placebo group

VC005 Placebo group with Local topical application

Locations(1)

Hangzhou First People's Hospital

Hangzhou, Zhejiang, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07598383

Related Trials

Evaluating the Safety and Tolerability of Baricitinib in Patients With Job Syndrome With Lupus-Like Disease and/or Atopic Dermatitis

NCT072629831 location

Real World Efficiency of Abrocitinib Treatment at Patients With Moderate to Severe Atopic Dermatitis Who Had Inadequate Response to Previous Biologic Therapies.

NCT068992041 location

A Study of BBT001 in Healthy Volunteers (HVs) and in Adult Patients With Moderate to Severe Atopic Dermatitis (AD)

NCT0723994710 locations

FIH Study to Evaluate the Tolerability of PF-07832837 in Healthy Adults and Patients

NCT065643895 locations

A Long-term Study of the Medicine Called Abrocitinib in Children Aged 2 Years and Older With Moderate to Severe Eczema

NCT0680728137 locations